Compare Banco Bilbao Vizcaya Argentaria SA (BBVA) vs Biogen Inc (BIIB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Bilbao Vizcaya Argentaria SA vs Biogen Inc — how do they compare? Banco Bilbao Vizcaya Argentaria SA trades at $28.6 (market cap $157.51B), while Biogen Inc trades at $202.7 (market cap $30.13B). The key difference: Banco Bilbao Vizcaya Argentaria SA is far larger — about 5.2× Biogen Inc's market cap, and Banco Bilbao Vizcaya Argentaria SA pays a 3.8% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BBVA | BIIB | |
|---|---|---|
Market Cap | $157.51B | $30.13B |
Sector | Financials | Health |
52-Week High | $28.50 | $216.63 |
52-Week Low | $17.96 | $128.93 |
Dividend Yield | 3.8% | — |
Enterprise Value | — | $37.20B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
